FDA, Amgen Shelve Sensipar Exclusivity Case
The U.S. Food and Drug Administration and Amgen Inc. on Monday halted litigation in D.C. federal court over denied exclusivity for blockbuster calcium-control drug Sensipar after agreeing to see if the...To view the full article, register now.
Already a subscriber? Click here to view full article